Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Share-based Compensation (2019 - 2023)

Historic Share-based Compensation for ADC Therapeutics (ADCT) over the last 5 years, with Q4 2023 value amounting to $2.2 million.

  • ADC Therapeutics' Share-based Compensation rose 2650594.44% to $2.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was $13.5 million, marking a year-over-year increase of 2682269.33%. This contributed to the annual value of $6.6 million for FY2024, which is 5133.01% down from last year.
  • Latest data reveals that ADC Therapeutics reported Share-based Compensation of $2.2 million as of Q4 2023, which was up 2650594.44% from $2.1 million recorded in Q3 2023.
  • In the past 5 years, ADC Therapeutics' Share-based Compensation ranged from a high of $8.1 million in Q1 2023 and a low of $216.0 during Q3 2019
  • In the last 5 years, ADC Therapeutics' Share-based Compensation had a median value of $14565.0 in 2022 and averaged $1.2 million.
  • In the last 5 years, ADC Therapeutics' Share-based Compensation crashed by 9963.19% in 2021 and then surged by 6016272.58% in 2023.
  • Quarter analysis of 5 years shows ADC Therapeutics' Share-based Compensation stood at $761.0 in 2019, then skyrocketed by 497928.91% to $3.8 million in 2020, then tumbled by 99.64% to $13539.0 in 2021, then crashed by 38.37% to $8344.0 in 2022, then surged by 26505.94% to $2.2 million in 2023.
  • Its last three reported values are $2.2 million in Q4 2023, $2.1 million for Q3 2023, and $1.1 million during Q2 2023.